BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22682976)

  • 21. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
    Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
    Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
    Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
    Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformationally-locked N-glycosides with selective β-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.
    Castilla J; Rísquez R; Cruz D; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
    J Med Chem; 2012 Aug; 55(15):6857-65. PubMed ID: 22762530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.
    Ivanova MM; Changsila E; Turgut A; Goker-Alpan O
    Am J Transl Res; 2018; 10(11):3750-3761. PubMed ID: 30662625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ambroxol reduces LPS toxicity mediated by induction of alkaline phosphatases in rat lung.
    Koyama I; Matsunaga T; Harada T; Kikuno A; Hokari S; Komoda T
    Clin Biochem; 2004 Aug; 37(8):688-93. PubMed ID: 15302612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical properties of beta-glucosidase in leukocytes from patients and obligated heterozygotes for Gaucher disease carriers.
    Michelin K; Wajner A; Bock H; Fachel A; Rosenberg R; Pires RF; Pereira ML; Giugliani R; Coelho JC
    Clin Chim Acta; 2005 Dec; 362(1-2):101-9. PubMed ID: 16039637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol.
    Pfeifer S; Zissel G; Kienast K; Müller-Quernheim J
    Eur J Med Res; 1997 Mar; 2(3):129-32. PubMed ID: 9113503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
    Grabowski GA; Goldblatt J; Dinur T; Kruse J; Svennerholm L; Gatt S; Desnick RJ
    Am J Med Genet; 1985 Jul; 21(3):529-49. PubMed ID: 3927728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uric acid plasma level and urine pH in rats treated with ambroxol.
    Drewa T; Wolski Z; Gruszka M; Misterek B; Lysik J
    Acta Pol Pharm; 2007; 64(6):565-7. PubMed ID: 18323253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-action ambroxol in treatment of chronic pain in Gaucher Disease.
    Pawlinski L; Krawczyk M; Fiema M; Tobor E; Kiec-Wilk B
    Eur J Pain; 2020 May; 24(5):992-996. PubMed ID: 31994807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.
    Zhang P; Zheng MF; Cui SY; Zhang W; Gao RP
    Endocr Metab Immune Disord Drug Targets; 2022; 22(6):658-662. PubMed ID: 34802413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease.
    Castilla J; Rísquez R; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
    Eur J Med Chem; 2015 Jan; 90():258-66. PubMed ID: 25461326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study.
    Narita A; Shirai K; Itamura S; Matsuda A; Ishihara A; Matsushita K; Fukuda C; Kubota N; Takayama R; Shigematsu H; Hayashi A; Kumada T; Yuge K; Watanabe Y; Kosugi S; Nishida H; Kimura Y; Endo Y; Higaki K; Nanba E; Nishimura Y; Tamasaki A; Togawa M; Saito Y; Maegaki Y; Ohno K; Suzuki Y
    Ann Clin Transl Neurol; 2016 Mar; 3(3):200-15. PubMed ID: 27042680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.
    Choy FY; Bouillon L; Laurin CA
    Am J Med Genet; 1987 Aug; 27(4):895-905. PubMed ID: 3425599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ambroxol effect on transepithelial electrical potential difference of isolated tracheal wall.
    Tyrakowski T; Sedlaczek A; Greczko I; Bartłomowicz M; Wojciechowska M
    Pol J Pharmacol; 1997; 49(1):53-8. PubMed ID: 9431553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in situ study of beta-glucosidase activity in normal and Gaucher fibroblasts with fluorogenic probes.
    Kohen E; Kohen C; Hirschberg JG; Santus R; Grabowski G; Mangel W; Gatt S; Prince J
    Cell Biochem Funct; 1993 Sep; 11(3):167-77. PubMed ID: 8403230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells.
    Ben Y; Chen J; Zhu R; Gao L; Bai C
    Respir Physiol Neurobiol; 2008 Apr; 161(2):111-8. PubMed ID: 18280225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels.
    Yang B; Yao DF; Ohuchi M; Ide M; Yano M; Okumura Y; Kido H
    Eur Respir J; 2002 May; 19(5):952-8. PubMed ID: 12030738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
    Trapero A; González-Bulnes P; Butters TD; Llebaria A
    J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.